February 27, 2023
RegMed Investors’ (RMi) closing bell: hunker down but, be aware of earnings backlash
February 22, 2023
RegMed Investors’ (RMi) closing bell: the sector’s continuous menace - sustainability
February 21, 2023
RegMed Investors’ (RMi) closing bell: extending losses as fear defines the cell/gene therapy sector with Q4 and FY22 earnings release bringing more pressures
February 17, 2023
RegMed Investors’ (RMi) closing bell: a concluding weekly reverse as the oversold sector was recognized closing positive after a bad morning
February 15, 2023
RegMed Investors’ (RMi) closing bell: inflation data drags on sector as an end of session closes positive
February 14, 2023
RegMed Investors’ (RMi) closing bell: cell/gene therapy sector sell-off deepens as higher inflation reading sent stocks downhill
February 13, 2023
RegMed Investors’ (RMi) closing bell: the sector’s upside bounce was expected
February 10, 2023
RegMed Investors’ (RMi) closing bell: sector shot down by inflationary “objects”
February 8, 2023
RegMed Investors’ (RMi) closing bell: cowboy up today but, like New England weather wait a day and it changes!
February 7, 2023
RegMed Investors’ (RMi) closing bell: the cell/gene therapy sector suffered tough love until late session to pop the A/D (advance/decline) Line positive
February 6, 2023
RegMed Investors’ (RMi) closing bell: show me the money
February 2, 2023
RegMed Investors’ (RMi) closing bell: Groundhog Day, share pricing saw its shadow following-through with a positive sector close
February 1, 2023
RegMed Investors’ (RMi) closing bell: We waited for Jerome – 25-basis points, Godot never really had a day in the limelight
January 31, 2023
RegMed Investors’ (RMi) closing bell: a reverse from Monday’s depths
January 30, 2023
RegMed Investors’ (RMi) closing bell: who said economics don’t matter?
January 27, 2023
RegMed Investors’ (RMi) closing bell: the tide came without a full moon effect
January 26, 2023
RegMed Investors’ (RMi) closing bell: investing in the soft sand at low tide
January 25, 2023
RegMed Investors’ (RMi) closing bell: sector finishes down yet, made strides late in session
January 24, 2023
RegMed Investors’ (RMi) closing bell: inclining positive session, yet … wait and watch
January 23, 2023
RegMed Investors’ (RMi) closing bell: sector nudges higher
January 20, 2023
RegMed Investors’ (RMi) closing bell: tug-of-war with sentiment backed-up by algorithms and electronic trading
January 19, 2023
RegMed Investors’ (RMi) closing bell: who says the cell/gene therapy sector is not fazed by economics?
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.